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Background: Intensive insulin therapy with continuous subcutaneous insulin infusion (CSII) devices or multiple
daily injections (MDI) reduces the risk of long-term vascular complications of type I diabetes (TID). Both treatments
are used routinely, but there is little evidence to demonstrate superiority of either treatment. If CSII treatment reduces
the risk of long-term complications or is associated with an improved quality of life (QoL), the additional cost of this
therapy may be compensated for by a reduction in long-term health expenditure. If there is no demonstrable
difference between treatments, health-care resources may be better invested elsewhere. This study aims to address this
gap in knowledge.
Methods/design: This is a pragmatic, randomised controlled trial (RCT). Fifteen centres, selected to represent a
population with a broad demographic, will recruit 316 patients, newly diagnosed with TID, aged between 7 months
and 15 years. Exclusion criteria include additional pathologies or treatments likely to affect glycaemic control and a
first-degree relative with TID. Randomisation to CSII or MDI is stratified for age, gender and recruiting centre.
The randomised treatment starts within 15 days of diagnosis. Patients will be trained to adjust their insulin dose
according to carbohydrate intake and blood glucose level.
Study visits coincide with routine clinic appointments at 3, 6, 9 and 12 months when data relating to routine clinical
assessments, adverse events and concomitant medications are collected. Health utilities questionnaires are completed
at each visit and a diabetes-specific QoL questionnaire (PedsQL) at diagnosis, 6 and 12 months.
The primary outcome is glycaemic control (HbA1c) at 12 months. Secondary outcome measures include QoL, insulin
use, growth and weight gain, adverse events and a health economics appraisal.
Discussion: This is the first adequately powered RCT comparing CSII and MDI in a non-selected population, treated
according to standard practice guidelines. It will produce data that are meaningful to individual patients and local and
national policymakers.
Trial registration: The study was registered with the European Clinical Trials Database on 4 November 2010, reference
2010-023792-25.
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Type I diabetes mellitus (TID) is a common disease of
childhood with more than 25,000 children and young
people being affected in the United Kingdom [1]. The
incidence of childhood TID in Europe is increasing by
3% to 4% a year, with the greatest increases being seen
in patients aged less than 5 years. It is predicted that the
European incidence of childhood TID will increase from
15,000 in 2005 to 24,400 in 2020, with a doubling in
numbers in children aged less than 5 years [2].
The psychosocial and financial cost of TID for patients,
the National Health Service (NHS) and society is consider-
able and is likely to increase. While the prevention and cure
of TID remains elusive, it is essential that insulin therapies
are used in the most effective and efficient manner.
The optimal treatment for TID would be compatible
with the best possible quality of life (QoL) for patients,
minimise the risk of acute and long-term complications,
and represent good value for money to the NHS. The
risk of developing long-term complications is strongly
related to the duration of TID and glycaemic control [3].
There is also convincing evidence that intensive insulin
regimes, in the form of multiple daily injections (MDI)
and continuous subcutaneous insulin infusions (CSII) or
insulin pumps, confer an additional benefit in the reduc-
tion in risk of long-term complications, over and above
improvements in glycaemic control [3]. These methods
of insulin therapy are now standard practice in the NHS,
although the use of CSII is less prevalent than in other
countries [4]. However, there is very little evidence to in-
dicate whether one treatment is superior to the other
[5]. The additional cost of insulin pump therapy is esti-
mated to be £1,700 per annum per patient [6]. If this
therapy is associated with an improvement in glycaemic
control or other measures of health and well-being, the
additional cost of this therapy may be offset by a reduc-
tion in the complications of TID. On the other hand, if
there is no significant difference between CSII and MDI,
this investment may be more appropriately directed to
other interventions and resources.
In observational studies, glycaemic control [7-11] and
QoL or treatment satisfaction [7,8] are reported to im-
prove following the introduction of CSII and the fre-
quency of severe hypoglycaemia is reported to fall [8,9,12].
For these reasons the National Institute for Health and
Care Excellence (NICE) recommends insulin pump ther-
apy as a treatment option for patients aged less than
12 years from diagnosis of TID, and for those aged 12 years
and above with inadequate glycaemic control on MDI or
disabling hypoglycaemia [13]. Approximately 19% of
paediatric patients with TID living in England and
Wales are treated with CSII [4].
However, when patients are assigned to treatment with
either MDI or CSII in the context of a randomisedcontrolled trial (RCT), the beneficial effect of CSII ther-
apy is less convincing. A Cochrane review reporting data
from seven paediatric RCTs [14] concluded that HbA1c
was 0.2% lower in patients treated with CSII compared
with those treated with MDI (95% confidence interval
(CI): 0.40% to 0.10%; P = 0.02). Six paediatric RCTs, in-
cluding three studies included in the Cochrane review,
were included in a recent meta-analysis that also con-
cluded that CSII had a favourable effect on HbA1c of
0.24% (95% CI: −0.41 to −0.07; P < 0.001), and required
lower doses of insulin than MDI (insulin dose 0.22 units
per kg per day lower, 95% CI: 0.31 to 0.14; P < 0.001)
[15]. However, there was no significant difference in the
rate of severe hypoglycaemic events or diabetic ketoaci-
dosis. A meta-analysis of QoL was not undertaken in
this meta-analysis or the Cochrane review, because the
tools used to measure QoL differed between studies.
Although trial evidence suggests a favourable effect of
CSII, it is important to note that there are a number of
weaknesses in most studies reported to date. Studies that
recruit patients with established TID treated with MDI,
may show an improvement with insulin pump therapy
for two reasons: (1) selection bias, since patients with
good glycaemic control who are satisfied with MDI ther-
apy are less likely to be approached or agree to participate
in these studies and (2) increased contact with diabetes
health-care professionals because at the start of insulin
pump therapy patients receive an intensive period of edu-
cation. Insulin analogues have been reported to improve
glycaemic control in paediatric practice [16] though only
one study uses analogue insulin for the treatment of all
patients using MDI [9]. The number of patients recruited
to studies is generally small, between 16 and 72, and these
studies are probably underpowered. Children aged less
than 5 years are over-represented. Furthermore, there are
only two multi-centre studies [17,18], one 2-centre study
[19] and three [20-22] of the ten RCTs are single-centre.
The observation period is 3.5 months in some studies, and
may be too brief for patients to acquire the skills required
to use CSII to its full potential [21-23]. In other studies
the observation period (4 to 6 months) may be too brief to
show patient fatigue in the use of this intensive therapy
[20,24-26].
To date no RCT has been delivered in the NHS set-
ting, where health-care services, lifestyle and diet differ
from those in which CSII and MDI have been studied
previously, and no study has investigated the health
economics of CSII.
The SCIPI (SubCutaneous Insulin: Pumps or Injec-
tions?) study will address these gaps in the current know-
ledge base, generating data that are generalisable to the
population of children and young people with TID, treated
within the NHS according to current treatment guidelines.
In doing so, we aim to make a valuable contribution to
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Methods/design
Ethical approval
The protocol has been approved by the Liverpool East Re-
search Ethics Committee, reference 10/H1002/80 and the
Medicines and Healthcare Products Regulatory Agency
(MHRA).
Local approvals have been obtained from Alder Hey
Children’s Hospital; Birmingham Children’s Hospital;
Doncaster Royal Infirmary; East Surrey Hospital; Ipswich
Hospital NHS Trust; Mid Staffordshire Hospital; Norfolk
and Norwich University Hospital; Oxford Children’s
Hospital; Queen’s Medical Centre, Nottingham; Royal
Blackburn Hospital; Royal Preston Hospital; Royal
Victoria Infirmary, Newcastle Upon Tyne; Sheffield
Children’s Hospital; Southampton General Hospital and
University Hospital of Wales, Cardiff. Recruitment to
the study at individual sites can only start once local
approvals have been obtained.
Design
This is a pragmatic, multi-centre RCT with an internal
pilot phase, in which insulin delivery by CSII is compared
to insulin delivery by MDI in children and young peopleRandom
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Figure 1 CONSORT flow diagram.aged 7 months to 15 years, newly diagnosed with TID. A
schematic representation of the study design is given in
Figure 1.The internal pilot study, with a sample size of 30
participants, tested the feasibility of recruitment. The study
proceeded to the full study phase when the following cri-
teria were met: (a) consent was obtained from more than
50% of eligible patients who were invited to participate and
(b) demographic characteristics, including age, ethni-
city, gender and deprivation score, were not considered
to be significantly different in the group of patients
who were recruited compared to those who declined.Centre and patient selection
Patients are recruited through 15 centres in the
United Kingdom located in Liverpool, Newcastle, Cardiff,
Oxford, Birmingham, Nottingham, Southampton, Preston,
Doncaster, Norwich, Redhill, Blackburn, Stafford, Sheffield
and Ipswich. Centres have been selected to ensure that pa-
tients are recruited from a demographically diverse popu-
lation. To be eligible to participate in the study, centres
must have ten or more patients treated with CSII within
their clinic population, and have sufficient resources to de-
liver the clinical aspects of the study protocol. All centres
have a study nurse. The inclusion and exclusion criteria
are given in Table 1.ise
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, screen patients by
ry, complete baseline
ents
onths for 12 months
Ac (primary outcome)
eight, body mass index,
urce use, health utilities
ry outcomes).
onths only: PedsQL
(secondary outcome)
Table 1 Participant inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Newly diagnosed type I diabetes
mellitus using standard diagnostic
practice
Treated previously for diabetes
Age 7 months to 15 years (inclusive) Haemoglobinopathy
Parent or legal representative of the
patient is willing to give consent for
the study
Co-existing pathology conditions
likely to affect glycaemic control
Parent or legal representative of the
patient is able to comply with the
treatment regimen and study visits
Psychological or psychiatric
disorders, e.g. eating disorders
Patient aged 8 years and over and is
able to adhere to the treatment
regimen and study visits
Receiving medication likely to
affect glycaemic control
Allergic to a component of
insulin aspart or insulin glargine
Thyroid in a non-euthyroid state
Coeliac disease and unable to
maintain a gluten-free diet
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Internal pilot
A total of 30 subjects were recruited providing 80%
power to detect a drop in the consent rate to 25% from
the assumed 50%, at the 5% significance level.
Full trial
The study has been powered to detect a difference in
HbA1c between treatment arms of 0.5%, this being the
threshold used by the Food and Drug Administration
and pharmaceutical industry to determine effectiveness
of new oral hypoglycaemic agents . A sample size of 143
in each group has 80% power to detect a difference in
mean HbA1c of 0.50%. To allow for a loss to follow-up
of 10%, 316 patients will be recruited.
Patient recruitment
Patients and families are given verbal and written infor-
mation about the study at the time of diagnosis of TID.
Since March 2014, a short film describing participants’
experiences has been available for eligible patients, their
parents and careers. Written, informed consent, and
where appropriate, assent, is obtained for all study par-
ticipants. The timing of consent is dependent on the
needs and wishes of the patient and family. However,
consent must be obtained within a time frame that al-
lows for the randomised treatment to start within 14 days
of diagnosis of TID.
Randomisation
Participants are randomised using a secure web-based
randomisation programme. Participants are randomised
to each treatment arm in a 1:1 ratio with stratification
for age and recruiting centre. The randomisation codelist is generated by a statistician using block randomisation
with the random variable block size method.
General procedures and measurements
Intervention
Patients are treated according to local clinical practice
from the time of diagnosis until the start of randomised
treatment.
Insulin therapy Starting insulin regimens are standar-
dised across both treatment arms, and then modified ac-
cording to clinical need by the treating clinician. Insulin
doses are titrated according to blood glucose levels re-
corded at home. For both treatment arms the total daily
dose (TDD) of insulin is calculated from body weight:
0.5 units per kg of body weight per day in pre-pubertal
patients and 0.7 units per kg of body weight per day in pu-
bertal subjects. Patients randomised to treatment with
MDI administer 50% of the TDD as insulin glargine
(a long-acting insulin analogue) once daily. The remaining
50% of the TDD is administered as insulin aspart (a short-
acting insulin analogue) in three divided doses, before
meals. Further boluses of insulin aspart are given when
10 g or more of carbohydrate are consumed. Patients
treated with CSII infuse 50% of the TDD as insulin aspart
at a basal rate, with the remaining 50% of the TDD being
given as boluses before meals. Additional boluses of insu-
lin aspart are given when 5 g or more of carbohydrate are
consumed. Correction doses for the treatment of high
blood glucose values for both treatment arms are calcu-
lated according to the 100 rule, in which the amount of in-
sulin required to reduce the blood glucose by 1 mmol/L is
calculated from the TDD of insulin [27].
Education for both treatment arms At entry to the
study, all participants complete a structured educational
program delivered to participants and their families in
accordance with the standards of the International Soci-
ety for Paediatric and Adolescent Diabetes [28]. All the
participants are trained in the use of MDI and the use of
the Roche Expert glucometer, whilst participants rando-
mised to CSII treatment are also trained in the use of
CSII pumps.
Data collection Table 2 shows the schedule of study
visits, timed to coincide with routine clinic appointments
according to the standards of the NICE guideline [29].
A full clinical history is taken at the time of diagnosis of
TID. A venous blood sample is collected at study entry for
the measurement of electrolytes, urea, pH, glucose and
HbA1c. Thyroid-stimulating hormone and free T4 are
measured to screen for disorders of thyroid function.
Tissue transglutaminase antibodies and immunoglobulin
A are measured to screen for coeliac disease. These blood
Table 2 Study procedures and data collection
Procedures Baseline Follow-up: scheduled 3-monthly clinic
visit from time of diagnosisDiagnosis Prior to start of treatment
T0 T + 3 T + 6 T + 9 T + 12
Assessment of eligibility criteria X
Signed consent form X
Randomisation X
Review of concomitant medications X X X X X
Review of insulin use (insulin requirements)
Patient diaries X X X X
General practitioner prescriptions X X X X
CSII pump download X X X X
Review of medical history X X X
Blood glucose measurement Xb X X X X X
Blood pH measurement X
Demographics X
Study intervention Xa
Physical exam
Height X X X X X
Weight X X X X X X
Injection sites X X X X
Symptom-directed (X) (X) (X) (X)
Assessment of adverse events (X) (X) (X) (X)
Clinical laboratory
HbA1c (local analysis) X X X X X
HbA1c (central analysis) X X X X X
Chemistry (X) X
Haematology (X) X
Urinalysis (X) X X X X
Patient completed measures
Patient PedsQL X X X
Parent PedsQL X X X
Health utilities index 2 X X X X X
Resource use: RN completed CRF X X X X X
(X), as indicated/appropriate.
aRandomised treatment will be commenced within 14 days of diagnosis; bmeasurement of blood glucose will be undertaken in the local hospital laboratory at
diagnosis and by glucometer at remaining time points. RN: research nurse, CRF: case report form.
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Details of concomitant medications are collected at each
study visit.Procedures for assessing efficacy
Primary outcome The primary outcome of the study is
HbA1c 12 months after diagnosis of TID. HbA1c will be
measured in the local laboratory and centrally at Alder
Hey Children’s NHS Foundation Trust in Liverpool.Samples will be collected at diagnosis and then at 3, 6, 9
and 12 months.
Secondary outcomes Secondary outcome measures
include insulin use, growth, weight gain, QoL, adverse
events and a health economics assessment.
Insulin requirements Insulin usage data are downloaded
from the CSII pumps for participants receiving CSII at
each study visit. Participants treated with MDI record
the insulin doses in patient-held diaries used as part of
Blair et al. Trials  (2015) 16:163 Page 6 of 9routine practice. Data are collected at each study visit.
At each follow-up visit the participant’s general practi-
tioner is contacted to ascertain the quantity of insulin
prescribed for the participant. This is compared to the
quantities recorded by participants to guard against sig-
nificant over-reporting.
Growth and weight gain Height and weight are mea-
sured at diagnosis, and then at the 3-, 6-, 9- and 12-
month study visits. Body mass index (BMI) standard
deviation score (SDS) are derived from 2007 World
Health Organisation growth data [30,31].
Adverse events Details of related adverse events, includ-
ing episodes of severe hypoglycaemia, diabetic ketoa-
cidosis, lipohypertrophy and injection/ infusion site
infections, are collected at each study visit and reported
according to the requirements of the MHRA. Adverse
events are captured by patients, carers and clinicians treat-
ing diabetes, and from interrogation of local hospital data-
bases for details of hospital attendances. Insulin injection
sites are examined at every visit for lipohypertrophy.
Quality of life QoL is assessed using validated diabetes-
specific QoL (PedsQL) questionnaire instruments [32]
prior to start of treatment then at 6 and 12 months after
diagnosis. Children and young people aged 5 to 7 years,
8 to 12 years and 13 to 18 years will use developmentally
appropriate versions, and the parental version is used for
all age groups [33].
Health economics analysis A cost utility analysis will be
conducted to estimate the incremental cost per quality-
adjusted life year (QALY) gained with CSII versus MDI.
The health economics analysis will adopt the perspective
of the NHS, and consider costs associated with both treat-
ment arms, CSII (insulin purchase, maintenance and use
of disposables) and MDI: insulin use, contact with health
professionals and costs associated with adverse events
including investigations, procedures, treatments and hos-
pitalisations. Time spent with diabetes health-care practi-
tioners (nurses, medical staff, dieticians and psychologists)
will be collected prospectively. Participants’ use of other
services will be collected by means of a health resource
use questionnaire prior to the start of randomised treat-
ment (for the previous 3 months) then at the 3-, 6-, 9- and
12-month study visits.
Unit cost data will be obtained from reference sources,
including routine hospital data (NHS reference costs [34])
and nationally published data [35]. Additionally, each
recruiting hospital will provide details of inpatient admis-
sions, including ward name and specialty (e.g. paediatric,
paediatric ICU, etc.); the average cost per bed day on the
ward and number of occupied bed days on the ward.QALYs will be estimated from patients’ (12 years and
over) and their parents’ or guardians’ responses to the
Health Utilities Index Mark 2 questionnaire. The six attri-
butes of this questionnaire (sensation, mobility, emotion,
cognition, self-care and pain) will be summarised into a
single UK-derived preference-based utility score [36].
Analysis
Primary outcome
The trial will be analysed and reported using the Consoli-
dated Standards of Reporting Trials (CONSORT) and the
International Conference on Harmonisation E9 guidelines.
A full and detailed statistical analysis plan will be devel-
oped prior to any comparative analysis of the trial data.
The main features of the statistical analysis plan are
included here.
A P value of 0.05 or less will be used to declare statis-
tical significance for all analyses. Rather than adjust for
multiplicity, relevant results from other studies already
reported in the literature will be taken into account in
the interpretation of results.
The primary analysis will use the intention-to-treat
principle, and a secondary analysis will be conducted
using the per-protocol approach. The purpose of the
per-protocol approach is to consider the robustness to
protocol deviations of the conclusions reached from the
analysis using the intention-to-treat principle.
The primary outcome HbA1c will be compared between
the trial groups using a two-group t-test. Difference in
means with 95% confidence intervals will be presented.
Analysis of covariance will be used to adjust for baseline
values and important prognostic factors.
Missing data will be monitored and strategies developed
to minimise its occurrence; however, as much data as
possible will be collected about the reasons for missing
data and this will be used to inform the handling of
missing data.
Health economics
Total costs will be calculated as the sum-product of re-
source use and unit cost for each patient. QALYs will be
calculated as the area under the utility-time curve over
12 months. Cost-effectiveness will be determined by the
ratio of the differences between treatment groups in
mean costs to QALYs. Uncertainty in the incremental
cost-effectiveness ratio (ICER) will be addressed through
the application of bootstrapping and the estimation of
cost-effectiveness acceptability curves [37]. A regression
analysis of cost and QALYs, with age, baseline HbA1c,
utility, cost [38] and other covariates as deemed appro-
priate, will be conducted to improve precision in the
cost utility estimate while conserving any correlation
between costs and benefits. Estimates of ICERs will be
compared with the £20,000 to £30,000 per QALY
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analysis in which trial results will be extrapolated to es-
timate lifetime costs and benefits and to capture long-
term micro- and macrovascular complications, will be
accomplished by using the CORE diabetes model [39].
Discussion
This study critically aims to compare the benefits and
disadvantages of insulin delivery by MDI and CSII for
children and young people. In developing this study
protocol, we have considered carefully the strengths and
weaknesses of previous studies. We have elected to recruit
patients with newly diagnosed TID, and excluded those
with affected first-degree relatives, to minimise the bias
that is likely to result from a patient’s or family’s previous
experience of success or failure of one treatment arm. To
ensure that the data generated in this study are generalis-
able to the population of children and young people with
TID, treated in the NHS we have: (1) selected centres with
diverse patient demographics, and demonstrated that the
characteristics of the population of patients who consent
to participate do not differ from those who decline; (2)
stated a requirement that patient management is directed
by local clinicians according to standard clinical practice
and (3) designed study visits to coincide with national
guidelines for the timing of clinic visits, thereby eliminat-
ing additional patient support and education that would
result from a more intensive visit schedule and maximis-
ing concordance with the study protocol. A wide range of
benefits and disadvantages of MDI and CSII have been re-
ported previously in observational trials and RCTs. In
selecting glycaemic control as the primary outcome, we
have chosen a parameter that can be robustly measured
and may be related to long-term outcomes and costs to
patients and health services [40,41]. While QoL is un-
doubtedly important, we are concerned that the paediatric
diabetes QoL questionnaires validated to date may not be
sufficiently sensitive to identify the ways in which these
modes of insulin delivery impact QoL differently. For this
reason QoL is a secondary outcome measure.
In delivering the study we face a number of challenges.
Patients have to be recruited shortly after the diagnosis of
TID, at a time when they and their families may feel over-
whelmed by the diagnosis and unable to consider par-
ticipation in a clinical trial. Treatment at the time of
diagnosis is determined by local practice, and in most
centres patients will be treated with MDI. Some pa-
tients and families develop a strong preference for this
treatment and are reluctant to consider CSII therapy.
To try to address this preference, we have made a short
film in which patients treated with MDI and CSII share
their experiences of their treatment and participation in
the study. Screening log data has shown that patients
who are approached soon after diagnosis are morelikely to consent to participate in the study, than those
approached later. We speculate that this may be be-
cause patients are less likely to have developed a prefer-
ence for MDI and are more open to the possibility of
treatment with CSII. We have used this information to
develop a recruitment strategy that includes an early
approach to families. For some centres, this will be
their first experience of CSII therapy from the time of
diagnosis. There are logistical challenges in educating
and supporting patients and families in establishing
CSII therapy within the time constraints of the study
protocol.
The SCIPI study will be the first RCT of MDI and CSII,
delivered in an unselected population and adequately pow-
ered to detect a difference in glycaemic control. The proto-
col has been developed carefully to ensure that the clinical
outcomes are meaningful for patients treated in the NHS.
We have also addressed the needs of national and local
policymakers, by including a range of outcomes important
to the development of clinical guidelines, including a ro-
bust health economics appraisal. For these reasons we be-
lieve this study will make a valuable contribution to the
care of children and young people with TID.
Trial status
The protocol has been approved by the Liverpool East
Research Ethics Committee, reference 10/H1002/80, and
was registered with the European Clinical Trials Data-
base, reference 2010-023792-25 on 4 November 2010.
The study was registered with the ISRCTN, registration
number ISRCTN2925527, on 12 November 2010. Site-
specific approval has been obtained at all recruiting sites.
In total, 250 participants have been recruited.
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